文献速递胸部肿瘤

克唑替尼治疗MET扩增非小细胞肺癌

Crizotinib in Patients With MET-Amplified NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-03-04

本研究在NCT00585195中评估克唑替尼(250 mg每日两次)对MET扩增NSCLC患者的疗效,按MET/CEP7比值分为高、中、低扩增三组。高扩增组客观缓解率最高(38.1%),中位缓解持续时间5.2个月,中位无进展生存期6.7个月;合并KRAS、BRAF或EGFR突变者未见缓解。

要点

  • 高MET扩增(MET/CEP7≥4)患者克唑替尼客观缓解率达38.1%。
  • 合并KRAS、BRAF或EGFR突变者未见客观缓解。
  • 联合检测MET及其他驱动基因有助于筛选获益人群。

核心结论

  • 高水平MET扩增的NSCLC患者对克唑替尼有响应,客观缓解率最高。
  • 联合检测MET与其他癌基因可能识别最可能从克唑替尼获益的患者。

研究设计与样本

  • 研究纳入NCT00585195中经当地FISH检测MET/CEP7比值≥1.8的NSCLC患者38例,接受克唑替尼250 mg每日两次。
  • 按MET/CEP7比值分为高扩增(≥4)、中扩增(>2.2至<4)、低扩增(≥1.8至≤2.2)三组。
  • 对存档肿瘤组织进行回顾性二代测序分析。

主要发现

  • 高、中、低扩增组分别有21、14、3例患者,客观缓解率分别为8/21(38.1%)、2/14(14.3%)、1/3(33.3%)。
  • 高、中、低扩增组中位缓解持续时间分别为5.2、3.8、12.2个月。
  • 高、中、低扩增组中位无进展生存期分别为6.7、1.9、1.8个月。
  • 二代测序可分析19例患者中15例(78.9%)检出MET扩增基因拷贝数≥6,其中6例(40%)出现客观缓解,2例合并MET外显子14改变。
  • 5例合并KRAS、BRAF或EGFR突变的患者均未观察到缓解。

临床怎么用

  • 对MET/CEP7比值≥4的高水平MET扩增NSCLC患者可考虑克唑替尼治疗。
  • 治疗前应联合检测MET扩增及其他驱动基因(KRAS、BRAF、EGFR)以筛选获益人群。

局限性

  • 本研究为小样本研究,高、中、低扩增组分别为21、14、3例。
  • 低扩增组仅3例,结果解读需谨慎。
  • 二代测序分析为回顾性,仅19例可分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: MET amplification is a rare, potentially actionable, primary oncogenic driver in patients with NSCLC. METHODS: The influence of MET amplification on the clinical activity of the ALK, ROS1, and MET inhibitor, crizotinib (250 mg twice daily), was examined in patients with NSCLC (NCT00585195) who were enrolled into high (≥4 MET-to-CEP7 ratio), medium (>2.2 to <4 MET-to-CEP7 ratio), or low (≥1.8 to ≤2.2 MET-to-CEP7 ratio) amplification categories. Retrospective next-generation sequencing profiling was performed on archival tumor tissue. End points included objective response rate (ORR), duration of response, and progression-free survival. RESULTS: A total of 38 patients with a MET-to-CEP7 ratio greater than or equal to 1.8 by local fluorescence in situ hybridization testing received crizotinib. All patients were response-assessable, among whom 21, 14, and 3 had high, medium, and low MET amplification, respectively. ORRs of 8 of 21 (38.1%), 2 of 14 (14.3%), and 1 of 3 (33.3%), median duration of response of 5.2, 3.8, and 12.2 months, and median progression-free survival values of 6.7, 1.9, and 1.8 months were observed for those with high, medium, and low MET amplification, respectively. MET amplification gene copy number greater than or equal to 6 was detected by next-generation sequencing in 15 of 19 (78.9%) analyzable patients. Of these 15 patients, objective responses were observed in six (40%), two of whom had concurrent MET exon 14 alterations. No responses were observed among five patients with concurrent KRAS, BRAF, or EGFR mutations. CONCLUSIONS: Patients with high-level, MET-amplified NSCLC responded to crizotinib with the highest ORR. Use of combined diagnostics for MET and other oncogenes may potentially identify patients most likely to respond to crizotinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021. PMID: 33676017. doi:10.1016/j.jtho.2021.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。